Study of Intravenous RXDX-107 in Patients With Solid Tumors

Sponsor

Hoffmann-La Roche (Industry)

Overall Status

Terminated

CT.gov ID

NCT02548390

Collaborator

(none)

Enrollment

Locations

Arm

Duration (Months)

23.3

Patients Per Site

1.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an open-label, Phase I/Ib, dose escalation study of intravenous RXDX-107 administered to subjects with advanced solid tumors. The study is designed to explore the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RXDX-107 and to define a recommended Phase 2 dose (RP2D)

Condition or Disease	Intervention/Treatment	Phase
Solid Tumor	Drug: RXDX-107	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

70 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1/1b, Multicenter, Open-Label Study of Intravenous RXDX-107 in Adult Patients With Locally Advanced or Metastatic Solid Cancer

Study Start Date :

Sep 1, 2015

Actual Primary Completion Date :

Sep 1, 2016

Actual Study Completion Date :

Sep 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: RXDX-107	Drug: RXDX-107 Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.

Arm

Intervention/Treatment

Experimental: RXDX-107

Drug: RXDX-107

Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.

Outcome Measures

Primary Outcome Measures

Phase 1: Safety profile of RXDX-107 as characterized by Adverse Events, ECG and laboratory abnormalities [Approx. 1 year]
AEs, ECG and Labs assessed according to NCI CTCAE V4.0
Phase 1: Maximum observed plasma drug concentration (Cmax) [Approx. 1 year]
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
Phase 1: Time to Cmax, by inspection (tmax) [Approx. 1 year]
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
Phase 1: Area under the drug concentration by time curve (AUC) [Approx. 1 year]
From time 0 to the time of the last detectable plasma concentration (AUC0-t)
Phase 1: Apparent plasma terminal elimination rate constant (λz) and associated terminal half life (t½) [Approx. 1 year]
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
Phase 1: Plasma clearance (CL) [Approx. 1 year]
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
Phase 1: Volume of distribution (Vz) [Approx. 1 year]
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
Phase 1: Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) [Approx. 6 months]
Phase 1b: Confirm RP2D [Approx. 1 year]
Number of participants with Treatment-related AEs, Labs changes from baseline, and QTc interval changes from baseline assessed according to NCI CTCAE V4.0, concomitant medication usage, including all supportive care provided, and preliminary anti-tumor activity per RECIST v1.1 as assessed by Investigator

Secondary Outcome Measures

Antitumor activity of RXDX-107 as measured by Objective Response Rate (ORR) [Approx. 1 year]
Per RECIST v1.1 as assessed by Investigator

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Confirmed relapsed or refractory locally advanced or metastatic solid cancer for whom no standard therapy is considered appropriate, or for whom standard therapy is considered intolerable.
18 years of age.
ECOG performance status of 0 or 1.
Life expectancy of at least 3 months.
Received the last dose of previous treatment / therapy before Day 1 of cycle 1:

28 days for cytotoxic chemotherapy, immunotherapy, whole brain radiotherapy, anticonvulsive therapy, stereotactic radiosurgery and major surgery
42 days for nitrosureas, mitomycin C, and liposomal anthracycline
14 days for non-cytotoxic cancer therapies and radiotherapy

Recovered from all toxic effects (excluding alopecia) of any prior anti-cancer therapy to Grade ≤ 1 or to the baseline laboratory values.
Adequate organ function and baseline laboratory values
Women of childbearing potential must have a negative serum pregnancy

Phase 1b: Patient must have measurable disease

Exclusion Criteria:

Receiving other experimental therapy
Known symptomatic brain mets or leptomeningeal involvement
Myocardial infarction in the previous 12 weeks. Active ischemia or any other uncontrolled cardiac condition such as angina pectoris, significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, or CHF.
Another concurrent illness which would preclude study conduct and assessment, uncontrolled: medical condition, active infection, risk of bleeding, diabetes mellitus, or pulmonary disease, or alcoholic liver disease, or primary biliary cirrhosis.
Malignancy within 3 years or active disease requiring treatment other than the target cancer. The exceptions are prostate cancer (Gleason grade < 6 with normalized PSA levels), treated in situ cervical, breast carcinoma, squamous or basal cell skin cancer.
Any condition that may compromise the ability to give written informed consent or to comply with the study protocol.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Florida Cancer Specialists	Sarasota	Florida	United States	34232
2	Johns Hopkins Medical Institute	Baltimore	Maryland	United States	21205
3	Tennessee Oncology, LLC	Nashville	Tennessee	United States	37203